Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)Takashi Seto, Kazuhiko Nakagawa, Mototsugu Shimokawa et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 50